Unprecedented results against a stubbornly hard-to-treat cancer are boosting optimism that other challenging tumours will be next.

The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.

Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.